Immune agonist antibodies face critical test

Immunotherapies that activate costimulatory receptors on T cells have failed so far in the clinic, but the first phase III trial of an agonist antibody in cancer has just begun and second-generation candidates are advancing.

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 19, 3-5 (2020)

doi: 10.1038/d41573-019-00214-5

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.